Viewing Study NCT01066468

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:48 PM
Ignite Modification Date: 2026-01-28 @ 12:17 PM
Study NCT ID: NCT01066468
Status: TERMINATED
Last Update Posted: 2012-03-13
First Post: 2010-02-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Myeloid Leukemia (CML) View
None Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) View
None Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic myeloid leukemia View
None CML View
None Philadelphia chromosome positive View
None acute lymphoblastic leukemia View
None PhGlivec, View
None Gleevec, View
None hypereosinophilic syndrome, View
None HES, View
None chronic eosinophilic leukemia, View
None CEL, View
None myelodysplastic syndrome, View
None MDS, View
None myeloproliferative disease, View
None MPD+ ALL View